The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.
Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.
Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.
Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.
Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.
Dr. Seminerio predicts how the future landscape will change for intravenous and subcutaneous biologics.
A gastroenterologist discusses the role of biosimilars in her clinical practice.
An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.
An expert gastroenterologist dissects a study that analyzed patient experience with intravenous and subcutaneous biological therapies.
Key topics in cost of intravenous and subcutaneous biologics are discussed by Dr Seminerio.
Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.
An expert lung doctor covers the main adverse events associated with antifibrotic agents and why it is necessary to develop newer pharmacotherapies to treat idiopathic and progressive pulmonary fibrosis.
The IQVIA vice president of industry relations and his talks featuring rapid-fire delivery of voluminous slide decks is a familiar figure in managed care circles. He is retiring in May 2025.
The IQVIA vice president and frequent speaker at pharmaceutical and managed care meetings shares some insights after he delivered the keynote talk at 2024 PBMI Annual National Conference held last week in Orlando, Florida. Long, a well-known figure in managed care circles, announced at the PBMI meeting that he is retiring in 2025.
Kerri Tanner, Pharm.D., chief pharmacy officer of PayerAlly, discusses the dynamic pricing models of Waltz Health and Free Market Health as a way for independent specialty pharmacies to compete.
Kerri Tanner, Pharm.D., the chief pharmacy officer of PayerAlly, says payers are looking for ways to rein in the escalating costs of specialty pharmacy drugs beyond the traditional techniques used by pharmacy benefit managers.
An expert clinician expands on efficacy results seen in a study comparing intravenous and subcutaneous biologics.
Dr Seminerio highlights the differences in billing between intravenous and subcutaneous biologics.
Patrick Cooney, president of The Federal Group, says elimination of spread pricing is one of the three key elements of the PBM legislation that he believes is likely to pass during the lame-duck session of Congress after the Nov. 5 election.
Patrick Cooney, president of The Federal Group, a Washington, D.C., lobbying firm says prospects for legislation passing this year, albeit during the post-election lameduck session, are good partly because the PBM legislation would produce Medicare savings that could be put toward other uses.
A medical expert discussses examples of successful prescription digital therapeutic (PDT) implementations and their impact on patient care, managed care coverage challenges related to PDTs, strategies to improve patient access, and methods for evaluating patient outcomes and satisfaction with PDTs.
An expert in diabetes care discusses tailoring diabetes quality measures to different types of patient populations.
Paul Noble, MD, provides his final thoughts surrounding unmet needs and breakthrough strategies for detection of IPF.
A gastroenterologist speaks about patient adherence when utilizing intravenous biologics.
Dr. Seminerio talks about how she positions intravenous and subcutaneous biologics and which patients benefit from each route of administration.
Arwen Podesta, MD, discusses key factors for the successful implementation of prescription digital therapeutics (PDTs) in clinical settings and how PDT manufacturers can support this process.
Experts discuss the importance of effective patient communication regarding prescription digital therapeutics (PDTs), the need for clinician training prior to PDT implementation, and key considerations for healthcare providers when prescribing these digital interventions.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, looks to the future of myelofibrosis treatment and discusses ongoing research and the evolving therapeutic landscape.
Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.
A renowned expert examines the essential elements for developing successful diabetes quality improvement programs.
